NASDAQ · PHARMACEUTICAL PREPARATIONS
Organigram Holdings Inc. OGI
6 fiscal years on record · CAD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
CAD 159.8M
EPS · FY24
CAD -0.48
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-28.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
CAD 159.8M
Revenue, FY2024 · full 6-year series below
Revenue
Net income
The company lost 28 cents on every revenue dollar this year.
Per share
CAD -0.48
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-22.3%
Net margin-28.4%
Return on assets-11.1%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+14.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+26.4%
+14.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.11B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CAD 407.9M
total assets, end of FY2024
Total assetsCAD 407.9M
Gross debtCAD 25,000.00
Current ratio4.92×
History
6 fiscal years
Every figure from documents filed with the SEC · CAD
Metric
2024
2022
2021
2020
2019
2018
Revenue CAD B
0.2
0.1
0.1
0.1
0.1
0.0
Operating income CAD B
−0.0
−0.0
−0.1
−0.1
0.0
0.0
EBITDA CAD B
−0.0
−0.0
−0.1
−0.1
0.0
0.0
Income tax CAD B
0.0
−0.0
0.0
−0.0
0.0
0.0
Net income CAD B
−0.0
−0.0
−0.1
−0.1
−0.0
0.0
EPS, diluted CAD
−0.48
−0.18
−0.51
−0.79
−0.07
0.16
Dividend / sh CAD
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
Shares out B
0.11
0.08
0.07
0.19
0.16
0.13
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
18 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 5 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed